ABCDE bundle

•

2 likes•2,424 views

Awakening & Breathing Coordination, Choice of sedative drugs, Delirium monitoring & management and Early mobility & exercise for machanically ventilated patients.

Viewers also liked

重症外傷に対する免疫応答Akinori Osuka

140531 患者安全能力＠臨床救急医学会

Ikegami Keiichi

Toxic Shock Syndrome

Yuichi Kuroki

Controlling ICU Agitation; Context Determines Strategy Ways to Facilitate Kno...hospira2010

Basis of nutrition

takejapanasia

外傷診療　資料Masaaki Sakuraya

Sedation in icuThomas Mphanza

救急領域における臨床教育の現状と工夫パネルディスカッション導入Ppt

えみ子浅香

New Insights in ICU Sedation

Dr.Mahmoud Abbas

災害拠点病院とは？

Yuichi Kuroki

Sedation & Paralysis in ICU- DR.RAGHUNATH ALADAKATTIapollobgslibrary

臨床推論2 感度, 特異度Katsushige Takagishi

急変前徴候への対応トレーニングの経験を活かしたRRS構築の一案

えみ子浅香

Art of sedation in icu

Surendra Patel

SedationAndrew Ferguson

Sedation practices in ICU

Abhijit Nair

臨床推論Katsushige Takagishi

Sedation , analgesia & paralysis

Dr.Venugopalan Poovathum Parambil

栄養リハのすすめ　スライドKeita Nakamura

熱傷勉強会（看護師向け）

Yuichi Kuroki

Viewers also liked (20)

重症外傷に対する免疫応答

140531 患者安全能力＠臨床救急医学会

Toxic Shock Syndrome

Controlling ICU Agitation; Context Determines Strategy Ways to Facilitate Kno...

Basis of nutrition

外傷診療　資料

Sedation in icu

救急領域における臨床教育の現状と工夫パネルディスカッション導入Ppt

New Insights in ICU Sedation

災害拠点病院とは？

Sedation & Paralysis in ICU- DR.RAGHUNATH ALADAKATTI

臨床推論2 感度, 特異度

急変前徴候への対応トレーニングの経験を活かしたRRS構築の一案

Art of sedation in icu

Sedation

Sedation practices in ICU

臨床推論

Sedation , analgesia & paralysis

栄養リハのすすめ　スライド

熱傷勉強会（看護師向け）

Recently uploaded

Knee anatomy and clinical tests 2024.pdf

vimalpl1234

planning for change nursing Management ppt

Thangamjayarani

For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls

Savita Shen $i11

TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...

kevinkariuki227

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...

GL Anaacs

Contact us if you are interested: Email / Skype : kefaya1771@gmail.com Threema: PXHY5PDH New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH ! Contact me on Threema or skype to start big business!! Hot-sale products: NEW HOT EUTYLONE WHITE CRYSTAL!! 5cl-adba precursor (semi finished ) 5cl-adba raw materials ADBB precursor (semi finished ) ADBB raw materials APVP powder 5fadb/4f-adb Jwh018 / Jwh210 Eutylone crystal Protonitazene (hydrochloride) CAS: 119276-01-6 Flubrotizolam CAS: 57801-95-3 Metonitazene CAS: 14680-51-4 Payment terms: Western Union,MoneyGram,Bitcoin or USDT. Deliver Time: Usually 7-15days Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet. Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details. We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.

Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx

Dr. Rabia Inam Gandapore

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Oleg Kshivets

RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

i3 Health

i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource. This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and Associate Division Director for Ambulatory Operations The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma. STATEMENT OF NEED Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL. Target Audience Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL). Learning Objectives 1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL 2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults 3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection

Ophthalmology Clinical Tests for OSCE exam

KafrELShiekh University

MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf

Jim Jacob Roy

Light House Retreats: Plant Medicine Retreat Europe

Lighthouse Retreat

Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf

Dr Jeenal Mistry

Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol that is rapidly distributed in the body and brain. Ethanol alters many neurochemical systems and has rewarding and addictive properties. It is the oldest recreational drug and likely contributes to more morbidity, mortality, and public health costs than all illicit drugs combined. The 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) integrates alcohol abuse and alcohol dependence into a single disorder called alcohol use disorder (AUD), with mild, moderate, and severe subclassifications (American Psychiatric Association, 2013). In the DSM-5, all types of substance abuse and dependence have been combined into a single substance use disorder (SUD) on a continuum from mild to severe. A diagnosis of AUD requires that at least two of the 11 DSM-5 behaviors be present within a 12-month period (mild AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria). The four main behavioral effects of AUD are impaired control over drinking, negative social consequences, risky use, and altered physiological effects (tolerance, withdrawal). This chapter presents an overview of the prevalence and harmful consequences of AUD in the U.S., the systemic nature of the disease, neurocircuitry and stages of AUD, comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and pharmacotherapies for AUD.

basicmodesofventilation2022-220313203758.pdf

aljamhori teaching hospital

ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS

Dr. Vinay Pareek

New Drug Discovery and Development .....

NEHA GUPTA

The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.

Triangles of Neck and Clinical Correlation by Dr. RIG.pptx

Dr. Rabia Inam Gandapore

Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx

Dr. Rabia Inam Gandapore

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...

Savita Shen $i11

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

bkling

Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.

How to Give Better Lectures: Some Tips for Doctors

LanceCatedral

Recently uploaded (20)

Knee anatomy and clinical tests 2024.pdf

planning for change nursing Management ppt

For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls

TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...

Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

Ophthalmology Clinical Tests for OSCE exam

MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf

Light House Retreats: Plant Medicine Retreat Europe

Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf

basicmodesofventilation2022-220313203758.pdf

ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS

New Drug Discovery and Development .....

Triangles of Neck and Clinical Correlation by Dr. RIG.pptx

Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

How to Give Better Lectures: Some Tips for Doctors

ABCDE bundle

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (20)

More from Yuichi Kuroki

More from Yuichi Kuroki (20)

Recently uploaded

Recently uploaded (20)